Neo Ivy Capital Management Boosts Stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Neo Ivy Capital Management lifted its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 371.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,528 shares of the medical equipment provider's stock after purchasing an additional 5,144 shares during the quarter. Neo Ivy Capital Management's holdings in Zimmer Biomet were worth $689,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of ZBH. Stonebridge Financial Group LLC bought a new stake in Zimmer Biomet in the fourth quarter valued at $25,000. Accredited Wealth Management LLC bought a new stake in shares of Zimmer Biomet during the fourth quarter worth $36,000. Kentucky Trust Co bought a new stake in shares of Zimmer Biomet during the fourth quarter worth $39,000. OFI Invest Asset Management bought a new stake in shares of Zimmer Biomet during the fourth quarter worth $40,000. Finally, Dunhill Financial LLC lifted its stake in shares of Zimmer Biomet by 86.6% during the fourth quarter. Dunhill Financial LLC now owns 444 shares of the medical equipment provider's stock valued at $47,000 after acquiring an additional 206 shares during the period. 88.89% of the stock is currently owned by institutional investors.

Zimmer Biomet Stock Up 0.4%

ZBH stock traded up $0.39 during trading on Thursday, reaching $92.68. 596,432 shares of the stock were exchanged, compared to its average volume of 1,794,466. The firm has a market cap of $18.34 billion, a P/E ratio of 20.80, a price-to-earnings-growth ratio of 1.95 and a beta of 0.78. Zimmer Biomet Holdings, Inc. has a twelve month low of $89.92 and a twelve month high of $116.86. The firm's 50 day moving average is $100.72 and its 200 day moving average is $105.04. The company has a current ratio of 1.91, a quick ratio of 0.99 and a debt-to-equity ratio of 0.43.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last issued its quarterly earnings results on Monday, May 5th. The medical equipment provider reported $1.81 EPS for the quarter, beating analysts' consensus estimates of $1.77 by $0.04. The company had revenue of $1.91 billion during the quarter, compared to the consensus estimate of $1.89 billion. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. Zimmer Biomet's revenue was up 1.1% on a year-over-year basis. During the same period last year, the business posted $1.94 earnings per share. As a group, research analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Insider Buying and Selling at Zimmer Biomet

In other Zimmer Biomet news, SVP Lori Winkler sold 1,443 shares of Zimmer Biomet stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total transaction of $150,649.20. Following the completion of the sale, the senior vice president now owns 8,768 shares of the company's stock, valued at $915,379.20. The trade was a 14.13% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.70% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the company. Stifel Nicolaus set a $115.00 price target on Zimmer Biomet and gave the stock a "buy" rating in a research report on Tuesday, May 6th. Morgan Stanley decreased their price target on Zimmer Biomet from $115.00 to $95.00 and set an "equal weight" rating for the company in a research note on Tuesday, May 6th. Needham & Company LLC restated a "hold" rating on shares of Zimmer Biomet in a research note on Friday, February 7th. Barclays decreased their price target on Zimmer Biomet from $118.00 to $112.00 and set an "underweight" rating for the company in a research note on Monday, February 10th. Finally, Robert W. Baird reduced their target price on Zimmer Biomet from $130.00 to $115.00 and set an "outperform" rating for the company in a research note on Tuesday, May 6th. Two analysts have rated the stock with a sell rating, eleven have assigned a hold rating and eight have issued a buy rating to the stock. According to MarketBeat, Zimmer Biomet presently has an average rating of "Hold" and an average target price of $111.53.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.